Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
1(5%)
Results Posted
11%(1 trials)
Terminated
2(10%)

Phase Distribution

Ph phase_2
1
5%
Ph not_applicable
3
14%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

21

all time

Status Distribution
Active(3)
Completed(9)
Terminated(2)
Other(7)

Detailed Status

Completed9
unknown7
Terminated2
Not yet recruiting1
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
1
Success Rate
81.8%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (25.0%)
N/A3 (75.0%)

Trials by Status

terminated210%
not_yet_recruiting15%
completed943%
unknown733%
enrolling_by_invitation15%
recruiting15%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT07319130Not Applicable

Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 Expression

Enrolling By Invitation
NCT07069842

The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment

Recruiting
NCT06657755

Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients

Completed
NCT06550947

ALDOA Expression in Bladder Urothelial Carcinoma

Not Yet Recruiting
NCT06485193

The Innate Immune Response and Enteric Nervous System in Crohn's Disease.

Terminated
NCT03986541

AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer

Completed
NCT06147960

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Unknown
NCT04445532

Hepatobiliary Tumors Tissue Samples Acquisition

Unknown
NCT05832593

Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.

Unknown
NCT05553080

Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Completed
NCT03920800

Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions

Completed
NCT01253668Phase 2

Brivanib Metastatic Renal Cell Carcinoma

Terminated
NCT03305133

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

Completed
NCT04122131

Fibrotic Focus in Breast Cancer

Unknown
NCT03820921

Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients With Pancreatic Cancer

Unknown
NCT02338427Not Applicable

Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis

Completed
NCT03692533Not Applicable

Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma

Unknown
NCT03160482

PACE4 in Thyroid Cancer

Completed
NCT03645915

GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors

Completed
NCT03078959

Prognostic Value of PD-L1 in NSCLC

Unknown

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
21